<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>LA092189-0232</title>
	</head>
	<body>
		<main>
			<p><P> September 21, 1989, Thursday, P.M. Final  </P> <P> P.M. BRIEFING;  </P> <P> IMMUNEX PLANS PRODUCT LINE SWITCH  </P> <P> Immunex Corp. today announced a plan that will transform it from a  research-dominated firm in medical biotechnology into a conventional  pharmaceutical company.  </P> <P> The 8-year-old company, based in Seattle, said it will achieve the transition  primarily by reacquiring rights to sell Immunex-developed products in the  United States. In return, its business partners will get rights to some other  Immunex products, primarily for overseas distribution.  </P> <P> Immunex uses gene-splicing and other biotechnology techniques to create  products for medical treatment.  </P></p>
		</main>
</body></html>
            